Study of Lipid Balance in Adult Sickle Cell SS or SC Patients at Steady State and According to Clinical Phenotypes and During Acute Complications Acronym : HDL2

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study aims to describe and/or searches for, in cohorts of adult sickle cell anemia (SCA) and SC sickle cell patients living in the French West Indies and followed by SCD Reference and Competence Centers: 1-lipids profiles and associations at steady state with occurrence of sickle cell disease (SCD) complications, 2-lipids profile evolution during and after prospective acute complications (vasoocclusive crises (VOC) and priapism), 3-lipids profile variation (inter /intra individuals) during 4 prospective years, 4- Genetic primary modulators of SCD complications, 5- insulin resistance (HOMA), free fatty acids and glycerol dosages, 6- lipids enzymes, lipidome and functionality of HDL in sub-groups of SCD population.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Aged from 18 years and over

• Be affected with Sickle cell anemia or SC sickle cell

• Living in French Caribbean Islands of Guadeloupe or Martinique and followed by physicians issued from a French West Indies Sickle Cell Reference or Competence Center

• At steady state in the last month (without acute complication)

• To have given a written consent after information on the study.

Locations
Other Locations
France
Centre de Référence de la Drépanocytose
NOT_YET_RECRUITING
Le Lamentin
Unité Transversale de la Drépanocytose
RECRUITING
Pointe À Pitre
Contact Information
Primary
Valérie HAMONY-SOTER
valerie.soter@chu-guadeloupe.fr
+590 590934686
Backup
Eunice Nubret
eunice.nubret@chu-guadeloupe.fr
+590 590 93 46 86
Time Frame
Start Date: 2022-11-30
Estimated Completion Date: 2028-11-30
Participants
Target number of participants: 350
Sponsors
Leads: Centre Hospitalier Universitaire de la Guadeloupe
Collaborators: Direction Générale de l'Offre de Soins

This content was sourced from clinicaltrials.gov